Investment Fact Sheet |
US Citizens
Please note that US shareholders can purchase BioMS shares through a registered broker and/or online trading service. Have more questions? Please email BioMS at info@biomsmedical.com or call toll-free 1-866-701-6033.
Investing Facts
- Working Capital: $78.4 million (as at March 31, 2009)
- Shares Outstanding: 91,009,323 (as at March 31, 2009)
- 52-week Range: $1.51-$4.10 (as at March 31, 2009)
- Fiscal Year-End: December 31st
- Listed on the Toronto Stock Exchange (TSX): Stock Symbol "MS"
Investing Highlights
- Dirucotide is the only novel agent for secondary progressive MS in phase III trials
- Dirucotide represents a new class of drug with potential significant advantages
- Dirucotide has blockbuster potential in a large underserved market
- Potential near-term value creating milestones
BioMS Medical Corporate Fact Sheet and Company Brochure:
|
|
|
Request Our Investor Package >>
Invest in Biotech